findmyKOL
Clinical trialNCT02242097CompletedPhase 2Interventional

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

SponsorNorthwestern UniversityEnrollment37Contiguous Stage II Mantle Cell LymphomaNoncontiguous Stage II Mantle Cell LymphomaStage I Mantle Cell LymphomaStage III Mantle Cell LymphomaStage IV Mantle Cell Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being done to see whether or not a drug called ibrutinib can be given to patients with mantle cell lymphoma (MCL) as maintenance therapy after induction chemotherapy. This drug blocks an enzyme that affects how the lymphocytes grow and survive. The investigators hope to learn how safe and effective ibrutinib is for treating patients with MCL after responding to induction chemotherapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Northwestern University

    Chicago, Illinois, United States

  • Northwestern University- Lake Forest Hospital

    Lake Forest, Illinois, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Cleveland Clinic

    Cleveland, Ohio, United States

  • University of Utah

    Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ibrutinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
12 Jan 2015
Primary completion
7 Dec 2021
Completion
5 Jan 2023
Last update posted
10 Jun 2026
Registered enrollment
37
Registry id
NCT02242097
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.